Andere talen Fuji Pharma Co., Ltd.

Aandelen

4554

JP3816200004

Vertraagde tijd Japan Exchange Andere beurzen 08:00:00 01-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.478 ^JPY	-1,20%		+2,35%	-15,01%

2023	Bel20 sluit voor de vijfde keer op rij in het rood	AM
2023	Bel20 kleurt volledig rood	AM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23-10-23
Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan	25-09-23
Alvotech, Fuji Pharma Win Marketing Approval in Japan for Stelara Biosimilar	25-09-23
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	06-09-23
Vistagen Therapeutics, Fuji Pharma Sign Exclusive Negotiation Deal for Japanese Market	05-09-23
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	05-09-23
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15-08-23
Mithra Receives Milestone Payment from Fuji Pharma; Shares Surge 11%	03-08-23
Fuji Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	11-05-23
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	13-01-23
Alvotech, Fuji Pharma Include New Biosimilar Candidate in Marketing Partnership in Japan	13-01-23
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate	13-01-23
Alvotech and Fuji Pharma Expands Partnership Adding A New Biosimilar Candidate	13-01-23
Mithra and Fuji announce approval of NEXTSTELLIS in Thailand	24-10-22
Alvotech Says Partner Fuji Pharma Submitted Application for Marketing Approval of Biosimilar Candidate in Japan	17-10-22
Fuji Pharma Co., Ltd. Submits Application for Marketing Approval of First Biosimilar Candidate in Japan	17-10-22
MÄRKTE ASIEN/Börsen knicken mit russischer Militäroperation ein	24-02-22
Fuji Pharma Co., Ltd. Provides Financial Guidance for the Fiscal Year Ending September 30, 2022	18-11-21
Fuji Pharma Provides Dividend Guidance for the Fiscal Year Ending September 30, 2022	18-11-21
Fuji Pharma Co., Ltd. Announces Consolidated Earnings Results for the First Half of Fiscal Year Ending September 30, 2021	20-05-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fuji Pharma Co., Ltd.

Aandelen

4554

JP3816200004

Andere talen

Filters